Form 4/A for ORIC Oric Pharmaceuticals, Inc.
Accepted 2023-02-17 00:00:00 ET · period of report 2022-12-15 · accession 0001209191-23-010607 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2023-02-17 | 2022-12-15 | ORIC | Chacko Jacob | Pres, CEO, Dir | S - Sale | $3.07 | -6,137 | 816.7K | -0.7% | -$18.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-15 | S | D | 6,137 | $3.07 | 816,652 | D | — | — | (F1) This amendment is filed to correct the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs reported in the Form 4 filed December 16, 2022 and does not represent a discretionary sale by the Reporting Person. |